NCT00892463View on ClinicalTrials.gov

Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Depressive Disorder, Major
Interventions
DRUG

Quetiapine (Seroquel) XR

50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER

NCT00892463 - Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder | Biotech Hunter | Biotech Hunter